Oruka Therapeutics (ORKA) Long-Term Investments (2016 - 2026)

Oruka Therapeutics' Long-Term Investments history runs 4 years deep, the most recent figure standing at $107.1 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 347.22% year-over-year to $107.1 million in Q1 2026; TTM through Mar 2026 was $107.1 million, a 347.22% increase from a year earlier, with the FY2025 full-year figure at $142.5 million, up 688.86% from the prior year.
• Long-Term Investments declined to $107.1 million in Q1 2026 per ORKA's latest filing, from $142.5 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $151.8 million in Q3 2025 and bottomed at $18.1 million in Q4 2024.
• The 3-year median for Long-Term Investments is $65.5 million (2025), against an average of $77.8 million.
• Across the five-year window, Long-Term Investments jumped 688.86% in 2025 and surged 347.22% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $18.1 million in 2024, then soared by 688.86% to $142.5 million in 2025, then fell by 24.85% to $107.1 million in 2026.
• Per Business Quant, the three latest ORKA Long-Term Investments figures stand at $107.1 million (Q1 2026), $142.5 million (Q4 2025), and $151.8 million (Q3 2025).